JP2002012557A - Peroral drug composition - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a composition which ameliorates an unpleasant odor and taste in the mouth without complicated processes and is useful to effectively carry out the correction of the taste. SOLUTION: This peroral drug composition is obtained by including (A) an active ingredient, (B) an antacid and (C) one or more kinds of perfumes selected from the group consisting of terpene hydrocarbons and terpene aldehydes.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an internal medicine composition in which an unpleasant odor is suppressed, and more particularly to a pharmaceutical composition, which eliminates an unpleasant odor and taste when taken, and has a high scent and taste correcting effect and a high ease of administration. The present invention relates to an excellent oral medicine composition.

[0002]

2. Description of the Related Art When an antacid is blended with a bitter drug such as aspirin or acetaminophen to prepare an oral preparation, the odor specific to the antacid and the bitterness, sourness, or astringency of the drug make it difficult to prepare the drug. It is not uncommon to have poor takeability. Especially for elderly people, chewable tablets or quick-dissolving tablets, which are attracting attention from the viewpoint of improving the ingestibility, are blended with physiologically active ingredients that have such unpleasant tastes as bitterness, acidity and astringency. If so, problems may arise, such as refusal of medication or, in some cases, taking with large amounts of water. A solid preparation for internal use is prepared by mixing such a physiologically active ingredient and an excipient in advance or performing appropriate granulation, and then forming a granule, or a binder, a disintegrant, a disintegration aid, and shaping. Tablets and lubricants, and compression-molded to give tablets. In general-purpose preparations, it is desired to reduce the amount of various additives from the viewpoint of miniaturization and safety in portability, and the effect of the physiologically active ingredient can be reduced with a small amount of additives. There is a demand for a formulation that not only exerts its effects, but also enhances usability and palatability.

[0003] In response to these demands, a method of coating the surface of a physiologically active ingredient to suppress dissolution of the physiologically active ingredient in the mouth and reduce unpleasant taste is disclosed in Japanese Patent Publication No. 64-5004 and Japanese Patent Laid-Open Publication No. Sho 63-63.
301815 and JP-A-61-152623.
In some cases, the release of the physiologically active ingredient in the living body varies, and there is a problem in application to a preparation requiring a precise dissolution performance, a complicated process is required for preparing these, and an organic solvent is used. There was a problem that it had to be used. Masking by the addition of magnesium sulfate The effect of the addition of JP-A-2-25428 or the like cannot be expected to provide a sufficient flavoring effect even in a small amount. Also, a method of inclusion is proposed as in JP-A-61-69729. However, when masking a physiologically active ingredient by the method, generally a larger amount of the host ingredient is used for the active ingredient. Cyclodextrin is required. This leads to an increase in the total amount of the preparation, which leads to worsening of the ingestibility. Further, there still remains a fundamental problem such as a delay in the elution rate of the included active ingredient, and it is considered that there is a serious problem particularly for an active ingredient which requires a quick effect.

[0004] Generally, it is widely known that antipyretics, analgesics, cold remedies and the like are formulated into tablets and granules for use. In this case, if the components are only tasteless and odorless components, taste can be achieved very easily. However, if it is attempted to achieve flavor by simply blending components having an unpleasant taste as in the present case and simply blending components such as sweeteners, a general method involves blending a large amount of flavor components. In many cases, the method becomes necessary or, on the contrary, it becomes a less-palatable flavoring method.

For example, sucrose is most commonly used as a sweetener, but saccharides such as mannitol and fructose, dipotassium glycyrrhizinate, and saccharin, sodium saccharin, aspartame and the like are also incorporated as synthetic sweeteners. In addition, sucrose, mannitol, fructose, xylitol, glucose and the like are not sufficiently effective even if the amount is increased, and increasing the amount increases the bitterness like aspartame, didipotassium glycyrrhizinate, saccharin and saccharin sodium. Sometimes. In any case, it was not always an effective method for improving the unpleasant aroma and taste in an oral preparation containing an active drug ingredient and an antacid.

[0006]

DISCLOSURE OF THE INVENTION The present invention has been made in view of the above circumstances, and is intended to improve unpleasant aroma and taste in the mouth and to perform effective flavoring without taking complicated steps. It is intended to provide a useful composition.

Means for Solving the Problems The inventors of the present invention have conducted intensive studies to achieve the above object, and as a result, in an oral medicine composition containing an antacid, a unique odor of the antacid and aspirin and the like were found. The present invention has been found that an unpleasant taste such as acidity of a drug active ingredient can suppress these unpleasant scents and tastes by blending a specific terpene compound to obtain a composition having excellent ingestibility. It was completed. That is, the present invention is characterized by containing (A) a drug active ingredient; (B) an antacid; and (C) one or more fragrances selected from the group consisting of terpene hydrocarbons and terpene aldehydes. The internal medicine composition is provided.

[0007]

BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in detail. (A) Component: Drug Active Ingredient As the drug active ingredient that can be used in the oral medicine composition of the present invention, aspirin, acetaminophen, ibuprofen, etenzamid, naproxen, diclofenac sodium, piroxicam, azulene, indomethacin, salicylic acid, ketoprofen, Isosorbide dinitrate, dihydrocodeine phosphate, ephedrine and its salts, phenylpropanolamine hydrochloride, chlorpheniramine maleate, theophylline, (anhydrous) caffeine,
Those having bitterness, acidity, and astringency, such as cephalexin, sulfisoxazole, and minerals, may be mentioned. These drug active ingredients may be used alone or in combination of two or more. Of these, aspirin, acetaminophen, ibuprofen, ethenzamide, dihydrocodeine phosphate, ephedrine salts (especially hydrochloride), chlorpheniramine maleate, and anhydrous caffeine are preferred,
Aspirin is particularly preferred. The content of the active ingredient (A) in the internal medicine composition of the present invention is preferably 10 to 90%, more preferably 20 to 85%, based on the total mass of the internal medicine composition.

Component (B): Antacid An antacid which can be used in the oral medicine composition of the present invention includes aminoacetic acid, magnesium silicate, synthetic aluminum silicate, synthetic hydrotalcite, magnesium oxide, dihydroxyaluminum.・ Amino acetate, aluminum hydroxide gel, dried aluminum hydroxide, mixed dried gel of aluminum hydroxide and magnesium carbonate, co-precipitated product of aluminum hydroxide and sodium hydrogen carbonate, co-precipitated of aluminum hydroxide, calcium carbonate and magnesium carbonate Products, a coprecipitated product of aluminum hydroxide / potassium aluminum sulfate, magnesium carbonate, calcium carbonate, magnesium aluminate metasilicate and the like. These antacids may be used alone or in combination of two or more. Of these, magnesium carbonate,
Aluminum glycinate, magnesium oxide, calcium carbonate, synthetic hydrotalcite, and magnesium oxide are preferred, and aluminum glycinate and magnesium carbonate are more preferred. The content of the antacid (B) in the internal medicine composition of the present invention is preferably 5 to 50%, more preferably 10 to 4 based on the total mass of the internal medicine composition.
0%.

Component (C): a fragrance selected from the group consisting of terpene hydrocarbons and terpene aldehydes <terpene hydrocarbons> The terpene hydrocarbons that can be used in the oral administration composition of the present invention include limonene, terpinene, terpinolene, and pinene. And monoterpenes such as camphene, myrcene, ocimene, and karen; sesquiterpenes such as pisabolene, zingiprene, curcumen, casinene, sesquibenihen, santalen, caryophyllene, cedren, and longifolene; . Of these, monoterpene hydrocarbons are preferred, and limonene is particularly preferred.

<Terpenaldehyde> Examples of the terpene aldehyde which can be used in the oral medicine composition of the present invention include monoterpenes such as citronellal, citral, cyclocitral, safranal, ferrandral, and perillaldehyde. Of these, citral is particularly preferred. As these fragrances, a single compound may be used, or a mixture containing them, for example, a plant extract may be used. Plant extracts containing these fragrances include orange oil, lemon oil and the like. The content of the fragrance (C) in the internal medicine composition of the present invention is preferably 0.1% based on the total mass of the internal medicine composition.
01-5%, more preferably 0.05-2.5%.

The internal medicine composition of the present invention may optionally contain other flavor components. Other flavor ingredients include menthol, citronellol, geraniol, linalool,
Terpene alcohols (or derivatives thereof) such as borneol, α-terpineol, nerol and nerolidol, terpene ketones (or derivatives thereof) such as mentone, camphor and carmentone, and others, octanal, decanal, neral, nonanal, (E )-
β-ocimene, dodecanal, α-copaen, γ-mulorene, β-sinensal, α-togen, (Z) -β
-Ocimene, undecanal, α-humulene, cis-sabinene hydrate, β-elemen, β-cubeben, decyl-acetate, (Z) -β-farnesene, nootkatone, germacrene D, cis-carbeol, nonyl acetate, 1 -Octanol, tetradecanal, tridecanal, α-sinensal, octyl acetate and the like. These flavor components may be used alone or in combination of two or more. Of these, menthol, borneol, geraniol, citronellol or derivatives thereof are preferred. When other flavor components are used, the content in the internal medicine composition of the present invention is preferably 0.001 to 0.05%, more preferably 0.005 to 0.5%, based on the total mass of the internal medicine composition. 02%. The ratio with the component (C) is preferably component (C): other perfume component (mass ratio) = 0.1: 100 to 1: 100, more preferably 0.5: 50 to 1:50.

The internal medicine composition of the present invention may contain additives usually used in the internal medicine composition, such as disintegrants, binders, lubricants, corrigents, disintegration aids, pigments, etc., if necessary. Can be freely and freely blended as long as the effect of the above is not hindered. Coating can also be performed with a coating agent. Disintegrants, as disintegration aids, cellulose and derivatives thereof, sucrose, lactose, saccharides such as sorbitol,
And starch and its derivatives. As a binder, hydroxypropyl cellulose (degree of substitution 53.4 to
77.5%), methylcellulose, gelatin, vinylpyrrolidone, partially pregelatinized starch, caramel and the like.

Examples of the lubricant include magnesium stearate, hydrogenated castor oil, silicone oil, stearic acid, talc and the like. Flavoring agents include sucrose, lactose, glucose, mannitol and the like. Examples of the coating agent include sugar (sucrose, hydroxypropylcellulose, shellac), glycerin, silicone resin, polyvinyl alcohol, macrogol, methacrylic acid copolymer, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone and the like.

The dosage form of the internal medicine composition of the present invention is not particularly limited, but solid preparations such as tablets, capsules, granules, powders, tablets, troches and chewables; solutions, elixirs and syrups And liquid preparations such as alcoholic beverages, emulsions, suspensions and the like. Among these, chewable (solid) and liquid preparations are preferred. (Method for producing solid preparation) (A) The active drug ingredient such as aspirin can be directly made into tablets after adding an additive, but usually, when a tablet is made, dry tablets such as lactose, anhydrous lactose, and crystalline cellulose are used. Binder,
After mixing with a disintegrant such as carmellose, it can be granulated and used. The average particle size when a drug active ingredient such as aspirin is granulated using such an additive varies depending on the shape of the particles and the level of unpleasant taste, but is preferably 10 to 1000 μm, more preferably 100-800
μm, particularly preferably 150 to 500 μm. When the average particle size is within this range, the particle size can be adjusted efficiently, and when a tablet is formed, the content is not uniform due to adhesion to a rotating plate, scattering properties, and selective adsorption in a supply line. This is preferable because no troubles such as the formation of the oxidizing agent occur. Further, it is preferable because it does not cause separation from other additives in the internal medicine composition and keeps uniformity.

As the antacid component (B), the raw materials may be simply blended as they are, but usually these components alone or a solution dissolved or dispersed in a solvent by adding an appropriate excipient is prepared by stirring. It is preferable to use granules using a granulator, a ribbon type mixer, a kneader or the like. In particular, a stirring-type granulator can be suitably used. The granulate can then be dried using a tray or a fluidized bed. Further, this is sieved and sized to obtain an appropriate particle size. Granulation can also be performed by spray drying in an air stream.

The component (C) is usually a liquid, and may be dispersed and supported on a part of the additives, blended and mixed,
It is also possible to granulate the masking particles containing the component (C) and mix them with the desired active ingredient. When granulated masking particles are used, the carrier of the component (C) includes carmellose calcium, croscarmellose sodium, crosslinked polyvinylpyrrolidone, gum arabic, cyclodextrin, etc., and gum arabic, cyclodextrin, etc. Powder is preferred. The surface area of the above-mentioned support is preferably 5000 m ² / g or more,
Those having 0 m ² / g or more are more preferable.

The fragrance used in the present invention can also be added to an antacid prepared in advance and blended. If the antacid is in the form of granules, it can be blended as it is, but if it is blended before preparing the granules, if it is heated above room temperature after granulation, the fragrance will vaporize significantly, so roll compression method etc. Is preferably performed. For example, 3 kg of magnesium carbonate was placed in an agitation type granulator FS-10J manufactured by Fukae Kogyo Co., Ltd., and 10 g of fragrance was dropped, stirred and uniformly dispersed, followed by ALEXANDE
It can be prepared by dry granulation with R WERK EINSPEIS type. (Manufacturing method of liquid preparation) A 30 L dissolving pot can be prepared by adding 500 g of acetaminophen, 500 ml of ethanol, and 15 L of water to make the mixture homogeneous, and further adding 10 g of TO-10 to a solution prepared by making 10 g of the fragrance uniform and dissolving.

[0018]

According to the present invention, by adding a specific terpene compound, an unpleasant aroma of an antacid and an unpleasant sourness of an active ingredient of a drug such as aspirin are simultaneously eliminated to correct a pleasant taste. Can be. Hereinafter, the present invention will be described specifically with reference to Examples and Comparative Examples, but the present invention is not limited to the following Examples.

[0019]

EXAMPLE 1 2600 g of aspirin was mixed with 400 g of corn starch in a V-type mixer V-5 (manufactured by Tokusui Co., Ltd.) for 10 minutes, and then roll-compressed with ALEXANDER WERK EINSPEIS.
Next, the granules were sized using a multi-stage sizing machine GRN-T-54-S (Nippon Granulator). The obtained granules were adapted to the granules of Japan Pharmacopoeia. On the other hand, magnesium carbonate and magnesium oxide were selected as antacids, and 1800 g, 900 g and 300 g of corn starch were added, respectively, and the mixture was mixed in a stirring granulator FS-10J type (manufactured by Fukae Kogyo KK) and mixed for 5 minutes. While continuing stirring, hydroxypropyl cellulose (degree of substitution 65.
(5%) A solution prepared by dissolving 60 g in 675 g of water was dropped and granulated. The granulated product was dried in a fluidized bed at 70 ° C. for 1 hour using SPI-A-FLOW type 5 (manufactured by Freund Corporation). This was sized using a multi-stage sizing machine (GRN-T-54-S type, manufactured by Nippon Granulator Co., Ltd.).
g, and 6 g of the fragrances shown in Table 1 are added.
The mixture was mixed for 10 minutes with Model-5 (manufactured by Tokuju Seisakusho), and 24 g of magnesium stearate was further added and mixed for 2 minutes. The aspirin granules and the antacid composition were mixed with a rotary tableting machine L-41 (manufactured by Hata Iron Works Co., Ltd.) to form the first layer of aspirin granules.
The antacid composition was tableted as a second layer to obtain a two-layer tablet (chew) having a diameter of 8 mm and an average mass of 229.2 mg.

[0020]

[Table 1]

[0021]

[Table 2]

A chewing preparation containing no fragrance was prepared using the same method as the above-mentioned preparation, and was chewed and taken by five professional subjects, and the odor of the antacid and the degree of unpleasant acidity were evaluated. . As a result, it was found that the preparation containing the fragrance had an unpleasant aroma and acidity improved.

[0023]

[Table 3]

Example 2 2600 g of aspirin was mixed with 400 g of lactose in a V-type mixer V-5 (manufactured by Tokuju Seisakusho) for 10 minutes, and then mixed with ALE.
Roll compression by XANDER WERK EINSPEIS type, then multi-stage type granulator GRN-T-54-S (Nippon Granulator)
And sized. The obtained granules were adapted to the granules of Japan Pharmacopoeia.
On the other hand, magnesium carbonate and aluminum glycinate were selected as antacids, and 1800 g, 900 g and lactose 300 g were added, respectively, and the mixture was placed in a stirring granulator FS-10J type (manufactured by Fukae Industry Co., Ltd.).
Mix for 5 minutes. While stirring, 675 g of hydroxypropylcellulose (substitution degree: 65.5%)
g of a solution dissolved in water was dropped and granulated. The granulated product was dried in a fluidized bed at 70 ° C. for 1 hour using SPI-A-FLOW type 5 (manufactured by Freund Corporation). This is a multi-stage granulator (GR
The granules were sized using NT-54-S type (manufactured by Nippon Granulator).
600 g of crystalline cellulose was added to 1530 g of the granules, and
Was added for 10 minutes using a V-type mixer V-5 (manufactured by Tokusui Seisakusho), and 24 g of magnesium stearate was added and mixed for 2 minutes. The aspirin granules and the antacid composition are tableted on a rotary tableting machine L-41 (manufactured by Hata Iron Works) using the aspirin granules as the first layer and the antacid composition as the second layer. Thus, a two-layer tablet (chewing agent) having a diameter of 8 mm and an average mass of 229.2 mg was obtained.

[0025]

[Table 4]

[0026]

[Table 5]

A chewing preparation containing no fragrance was prepared using the same method as the above-mentioned preparation, and chewed by five expert subjects and taken, and the odor of the antacid and the degree of unpleasant acidity were evaluated. . As a result, it was found that the preparation containing the fragrance had an unpleasant aroma and acidity improved.

[0028]

[Table 6]

Example 3 2600 g of aspirin was mixed with 400 g of corn starch in a V-type mixer V-5 (manufactured by Tokusui Seisakusho) for 10 minutes, then roll-compressed with an ALEXANDERWERK EINSPEIS type, and then multistage sized. The particles were sized using a device GRN-T-54-S (manufactured by Nippon Granulator). The obtained granules were adapted to the granules of Japan Pharmacopoeia. On the other hand, magnesium carbonate and magnesium oxide were selected as antacids, and 1800 g, 900 g and 300 g of corn starch were added, respectively, and the mixture was mixed in a stirring granulator FS-10J type (manufactured by Fukae Kogyo KK) and mixed for 5 minutes. While continuing to stir, add hydroxypropyl cellulose (degree of substitution 65.5) from above.
%) A solution obtained by dissolving 60 g in 675 g of water was dropped and granulated. The granulated product was dried in a fluidized bed at 70 ° C. for 1 hour using SPI-A-FLOW type 5 (manufactured by Freund Corporation). This was sized using a multi-stage sizing machine (GRN-T-54-S type, manufactured by Nippon Granulator Co., Ltd.).
g and then 6 g of the fragrances shown in Table 1
The mixture was mixed for 10 minutes with a V-5 type (manufactured by Tokuju Seisakusho), and 24 g of magnesium stearate was further added and mixed for 2 minutes. The above aspirin granules and this antacid composition were converted into the first aspirin granules using a rotary tableting machine L-41 (manufactured by Hata Iron Works).
The antacid composition was tableted as a second layer to obtain a two-layer tablet (chewing agent) having a diameter of 8 mm and an average mass of 229.2 mg.

[0030]

[Table 7]

[0031]

[Table 8]

A chewing preparation containing no fragrance was prepared using the same method as the above preparation, and chewed by five expert subjects, and the antacid was smelled and the degree of unpleasant acidity was evaluated. . As a result, it was found that the preparation containing the fragrance had an unpleasant aroma and acidity improved.

[0033]

[Table 9]

Example 4 2600 g of aspirin was mixed with 400 g of crystalline cellulose in a V-type mixer V-5 (manufactured by Tokusui Seisakusho) for 10 minutes, and then roll-compressed with an ALEXANDERWERK EINSPEIS type, followed by multistage alignment. The granules were sized using a granulator GRN-T-54-S (Nippon Granulator). The obtained granules were adapted to the granules of Japan Pharmacopoeia. On the other hand, synthetic hydrotalcite was selected as an antacid, 2700 g and 300 g of corn starch were added, respectively, and the mixture was mixed in a stirring type granulator FS-10J type (manufactured by Fukae Industry Co., Ltd.) and mixed for 5 minutes. While stirring, 60 g of gelatin from the top
A solution dissolved in 5 g of water was dropped and granulated. The granulated product was dried in a fluidized bed at 70 ° C. for 1 hour using SPI-A-FLOW type 5 (manufactured by Freund Corporation). This was sized using a multi-stage sizing machine (GRN-T-54-S type (manufactured by Nippon Granulator Co., Ltd.). To 1530 g of the granules, 600 g of crystalline cellulose was added, and 12 g of the fragrance shown in Table 3 was further added. The mixture was mixed for 10 minutes with a V-5 model (manufactured by Tokuju Seisakusho), and 24 g of magnesium stearate was further added and mixed for 2 minutes.The aspirin granules and the antacid composition were mixed with a rotary tableting machine L. Aspirin granules were tabletted as a first layer and an antacid composition as a second layer using Model-41 (manufactured by Hata Ironworks Co., Ltd.), and had a diameter of 8 mm and an average mass of 229.
2 mg of a two-layer tablet (chewing agent) was obtained.

[0035]

[Table 10]

[0036]

[Table 11]

A chewing preparation containing no fragrance was prepared using the same method as the above-mentioned preparation, and chewed and taken by five specialized subjects, and the odor of the antacid and the degree of unpleasant acidity were evaluated. . As a result, it was found that the preparation containing the fragrance had an unpleasant aroma and acidity improved.

[0038]

[Table 12]

Example 5 2600 g of aspirin was mixed with 400 g of corn starch in a V-type mixer V-5 (manufactured by Tokusui Seisakusho) for 10 minutes, then roll-compressed with an ALEXANDERWERK EINSPEIS type, and then multistage sized. The particles were sized using a device GRN-T-54-S (manufactured by Nippon Granulator). The obtained granules were adapted to the granules of Japan Pharmacopoeia. On the other hand, magnesium carbonate and magnesium oxide were selected as antacids, and 1800 g, 900 g and 300 g of corn starch were added, respectively, and the mixture was mixed in a stirring granulator FS-10J type (manufactured by Fukae Kogyo KK) and mixed for 5 minutes. While continuing stirring, hydroxypropyl cellulose (degree of substitution 65.4)
%) A solution obtained by dissolving 60 g in 675 g of water was dropped and granulated. The granulated product was dried in a fluidized bed at 70 ° C. for 1 hour using SPI-A-FLOW type 5 (manufactured by Freund Corporation). This was sized using a multi-stage sizing machine (GRN-T-54-S type, manufactured by Nippon Granulator Co., Ltd.).
V-type mixer
The mixture was mixed for 10 minutes with a V-5 type (manufactured by Tokuju Seisakusho), and 24 g of magnesium stearate was further added and mixed for 2 minutes. The above aspirin granules and this antacid composition were converted into the first aspirin granules using a rotary tableting machine L-41 (manufactured by Hata Iron Works).
The layer and the antacid composition were tableted as a second layer to obtain a two-layer tablet (chew) having a diameter of 8 mm and an average mass of 229.2 mg.

[0040]

[Table 13]

[0041]

[Table 14]

A chewing preparation containing no fragrance was prepared using the same method as the above-mentioned preparation, and was chewed and taken by five expert subjects, and the odor of the antacid and the degree of unpleasant acidity were evaluated. . As a result, it was found that the preparation containing the fragrance had an unpleasant aroma and acidity improved.

[0043]

[Table 15]

Examples 6 and 7 Tablet-type solid preparations were prepared in the same manner as in Example 1 using the components shown in Table 16 below. In addition, a preparation containing no fragrance was prepared using the same method,
The odor of the antacid and the degree of unpleasant acidity were evaluated by humans. As a result, it was found that the preparation containing the fragrance had an unpleasant aroma and acidity improved.

[Table 16]

(Liquid preparation) In a 50 L mixing pot, 200 g of acetaminophen, 2.5 g of chlorpheniramine maleate, 5 g of dihydrocodeine phosphate, 18 g of ephedrine hydrochloride, 24 g of anhydrous caffeine, 20 g of magnesium carbonate, 1200 g of sucrose, D -Sorbitol 70%
250 g of the liquid, 35 g of caramel, 0.2 g of limonene and 0.1 g of citral were taken and homogenized with a homomixer. Unit: mg mass% in g acetaminophen 200 6.67 chlorpheniramine maleate 2.5 0.08 dihydrocodeine phosphate 5 0.16 ephedrine hydrochloride 18 0.60 anhydrous caffeine 24 0.80 magnesium carbonate 200. 67 White sugar 1200 40.00 D-sorbitol 70% liquid 250 8.33 Caramel 35 0.01 Limonene 0.2 0.01 Citral 0.1 0.33 Water 1245.2 42.34 Total 3000.0 100 Using the same method as the preparation, a preparation containing no fragrance was prepared, and five specialized subjects evaluated the odor of the antacid and the degree of unpleasant acidity. As a result, it was found that the preparation containing the fragrance had an unpleasant aroma and acidity improved.

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁷ Identification symbol FI Theme coat ゛ (Reference) A61K 31/192 A61K 31/192 31/616 31/616 47/06 47/06 47/08 47/08 A61P 25/04 A61P 25/04 F-term (reference) 4C076 AA11 AA40 AA49 BB01 CC01 DD22T DD24T DD25T DD27T DD29T DD30T DD34T DD40T DD51T FF52 4C084 AA16 MA05 MA16 MA35 MA52 NA09 ZA071 ZA072 ZA080AAMA MA4MA 4C206 AA01 AA02 DA24 DB18 GA07 GA31 MA05 MA11 MA36 MA55 MA72 NA09

Claims (5)

[Claims] 1. A composition comprising (A) a drug active ingredient; (B) an antacid; and (C) one or more fragrances selected from the group consisting of terpene hydrocarbons and terpene aldehydes. Oral medicine composition. 2. The internal medicine composition according to claim 1, wherein the fragrance (C) is d-limonene. 3. The internal medicine according to claim 1, wherein (A) the active drug component is one or more selected from the group consisting of aspirin, acetaminophen, ibuprofen, and etenzamid. Composition. 4. The internal medicine composition according to claim 1, which is a chewable (chewable) internal medicine. 5. The internal medicine composition according to claim 1, wherein the composition is a liquid oral medicine.